[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]

Related Experiment Video

Updated: Apr 20, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Capucine Baldini1, Boris Duchemann1, Antoine Hollebecque1

  • 1Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

Bulletin Du Cancer
|December 5, 2014
PubMed

Insights

Targeting the Ras/Raf/Mek/Erk pathway, crucial in cancer growth, offers new therapeutic options for Kras or Braf mutated solid tumors. This review analyzes these treatments, their toxicities, and resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • The Ras/Raf/Mek/Erk pathway is integral to tumor progression, influencing cell proliferation, survival, differentiation, and angiogenesis.
  • Hyperactivation of this pathway, often due to Kras or Braf mutations, is a significant driver of tumorigenesis.
  • Mek inhibitors represent a promising therapeutic strategy for cancers with activated Ras/Raf/Mek/Erk signaling.

Purpose:

  • To review the Ras/Raf/Mek/Erk pathway's role in cancer.
  • To describe emerging therapeutic strategies targeting this pathway in solid tumors.
  • To analyze predictive factors for treatment response and mechanisms of resistance.

Summary:

  • The Ras/Raf/Mek/Erk pathway is a critical regulator of cellular processes involved in cancer development.
  • Gain-of-function mutations in Kras or Braf frequently lead to pathway hyperactivation, driving tumor growth.
  • Mek inhibitors are emerging as targeted therapies for Kras or Braf-mutated cancers, with ongoing research into predictive biomarkers and resistance.

Impact:

  • Provides a comprehensive overview of the Ras/Raf/Mek/Erk pathway in oncology.
  • Highlights the therapeutic potential of Mek inhibitors in specific cancer types.
  • Addresses key challenges in targeted cancer therapy, including response prediction and resistance.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

847

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K